MRK · News · 20261104N

Bravecto Product Authorization

Merck & Co., Inc. · 2026-11-04 · Importance 41 · Surprise 60

Merck’s antiparasitic treatment Bravecto received emergency use authorization from the U.S. FDA for treating new screwworm infestations in dogs and puppies. The authorization expands Bravecto’s use beyond certain flea infestations, for which its chewable tablets are already available in the United States. The report describes a new use addressing a critical parasitic threat in canines.

Key facts

• Bravecto chewable tablets are already available in the U.S. for treatment and prevention of certain flea infestations. source